Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase — Oct 18th, 2024

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy now. Navigating the Healthcare Landscape: Investment Opportunities and Growth Tr...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Dividend Stocks Are Primed for a Comeback in 2025 — Dec 7th, 2024

With highflying tech stocks looking expensive and bonds losing appeal​, ​some investors turn to dividend payers​. Continue reading View comments...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Dividend Stocks Are Primed for a Comeback in 2025 — Dec 7th, 2024

With highflying tech stocks looking expensive and bonds losing appeal​, ​some investors turn to dividend payers​. Continue reading View comments...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Dividend Stocks Are Primed for a Comeback in 2025 — Dec 7th, 2024

With highflying tech stocks looking expensive and bonds losing appeal​, ​some investors turn to dividend payers​. Continue reading View comments...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

Dividend Stocks Are Primed for a Comeback in 2025 — Dec 7th, 2024

With highflying tech stocks looking expensive and bonds losing appeal​, ​some investors turn to dividend payers​. Continue reading View comments...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase — Oct 18th, 2024

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy now. Navigating the Healthcare Landscape: Investment Opportunities and Growth Tr...

Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase — Oct 18th, 2024

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy now. Navigating the Healthcare Landscape: Investment Opportunities and Growth Tr...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. — Nov 11th, 2024

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms. The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (im...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

AbbVie Stock Slides on Schizophrenia Drug Study Failure — Nov 11th, 2024

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t — Oct 26th, 2024

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors. Continue reading View comments...

Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase — Oct 18th, 2024

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy now. Navigating the Healthcare Landscape: Investment Opportunities and Growth Tr...